Applying Lucentis for the treatment of retinopathy of prematurity
https://doi.org/10.21516/2072-0076-2022-15-4-45-48
Abstract
Purpose: to evaluate the efficacy of Lucentis for the treatment of retinopathy of prematurity (ROP). Material and methods. 51 infants (102 eyes) with the gestational age between 24 and 33 weeks were given intravitreal injections of Lucentis, All patients selected had ROP stages I+, II+, III or III+ in zone 1, stage III+ in zone 2, or aggressive posterior ROP. The procedure was performed under general anesthesia; the dose, technique and the number of Lucentis injections conformed with the recommendations given in Lucentis instruction for use. If indicated, retinal laser photocoagulation was given after intravitreal injections using Supra (Quantel Medical, France) and Lachta-Mylon (Russia, Lasermedservis) laser equipment. Results. Clinical efficacy of intravitreal administration of Ranibizumab in infants with aggressive posterior ROP, zone 1 ROP, Stage III of zone 2 ROP was determined at 86.3 % (with no more than two injections). If ROP remains active after two injections, a change of therapy is recommended. Vascularization was noted to be complete in 51 % of cases. Conclusion. To achieve a maximum treatment effect of ROP with Lucentis, strict observation of indications criteria must take place.
About the Authors
S. V. Lesovoy
Z.A. Bashlyaeva Children's City Clinical Hospital
Russian Federation
Russian Federation
Sergey V. Lesovoy — ophthalmic surgeon, head of the ophthalmological department
28, Geroev Panfilovtsev St., Moscow, 125373
O. A. Boginskaya
Z.A. Bashlyaeva Children's City Clinical Hospital
Russian Federation
Russian Federation
Olga A. Boginskaya — Cand. of Med. Sci., ophthalmologist, ophthalmological department
28, Geroev Panfilovtsev St., Moscow, 125373
References
1. Darlow B.A., Gilbert C. Retinopathy of prematurity — A world update. Semin. Perinatol. 2019; 43 (6): 315–6. doi:10.1053/j.semperi.2019.05.001
2. Smith L.E., Hard A.L., Hellström A. The biology of retinopathy of prematurity: How knowledge of pathogenesis guides treatment. Clin. Perinatol. 2013; 40 (2): 201–14. doi:10.1016/j.clp.2013.02.002
3. Kim S.J., Port A.D., Swan R., et al. Retinopathy of prematurity: A review of risk factors and their clinical significance. Surv. Ophthalmol. 2018; 63 (5): 618–37. doi:10.1016/j.survophthal.2018.04.002
4. Sankar M.J., Sankar J., Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst. Rev. 2018; 1 (1): CD009734. doi:10.1002/14651858.CD009734.pub3
5. Lepore D., Quinn G.E., Molle F., et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018; 125 (2): 218–26. doi:10.1016/j.ophtha.2017.08.005
6. Wong R.K., Hubschman S., Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015; 35 (4): 675–80. doi:10.1097/IAE.0000000000000578
7. Hartnett M.E. VEGF antagonist therapy for ROP. Clin. Perinatol. 2014; 41 (4): 925–43. doi:10.1016/j.clp.2014.08.011
8. Astasheva I.B., Shevernaya O.A. Comparison of the laser photocoagulation types efficacy in the treatment of retinopathy of prematurity. Rossiyskaya detskaya oftalmologiya. 2014; 1: 25–9 (in Russian).
9. Rybus-Kalinowska B., Kwiatkowski S., Chojnacka K., Jochem J. Retinopathy of prematurity – etiopathogenesis and treatment. Pediatr. Med. Rodz. 2017; 13 (1): 22–8. doi:10.15557/PiMR.2017.0002
10. Young T.L., Anthony D.C., Pierce E., Foley E., Smith L.E. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J. AAPOS. 1997; 1 (2): 105–10. doi:10.1016/s1091-8531(97)90008-2
11. Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol. Scand. 2001; 79 (5): 435–40. doi:10.1034/j.1600-0420.2001.790502.x
12. Wang S., Zhang G., Shenzhen S. Screening for Retinopathy of Prematurity Cooperative Group Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis. Int. J. Ophthalmol. 2020; 13 (5): 806–15. doi:10.18240/ijo.2020.05.17
13. Carroll L., Owen L.A. Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions. Explor. Med. 2020; 1: 4–26. doi:10.37349/emed.2020.00002
14. Hard A., Hellström A. On the use of antiangiogenic medications for retinopathy of prematurity. Acta Paediatr. 2011; 100 (8): 1063–5. doi:10.1111/j.16512227.2011.02330.x
15. Sato T., Wada K., Arahori H., et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am. J. Ophthalmol. 2012; 153 (2): 327–33. doi:10.1016/j.ajo.2011.07.005
16. Hoerster R., Muether P., Dahlke C., et al. Serum concentration of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013; 91 (1): e 74–5. doi:10.1111/j.17553768.2012.02469.x
17. Sadovnikova N.N., Prisich N.V., Brzeskiy V.V. The role of VEGF inhibition in the treatment of retinopathy of prematurity. Rossiyskaya pediatricheskaya ophthalmologiya. 2016 11 (4): 212–20 (in Russian). doi:10.18821/1993-1859-2016-11-4-212-220
18. Sidorenko E.E., Nazarenko A.O., Sidorenko E.I., Obrubov S.A. Anti-VEGF therapy by Ranibizumab in retinopathy of prematurity. Rossiyskaya detskaya ophthalmologiya. 2019; 3: 17–21 (in Russian). doi:10.25276/2307-6658-2019-3-17-21
19. Product monograph Lucentis. Registration code: ЛСР-004567/08. 15.06.2020 (in Russian). Available at: https://www.novartis.ru/sites/www.novartis.ru/files/product-info/2020-06-15_Lucentis_NPI_v0.1-full_version.pdf
20. Tran K., Cernichiaro-Espinosa L.A., Berrocal A. Management of retinopathy of prematurity Use of Anti-VEGF therapy. Asia Pac. J. Ophthalmol. 2018; 7 (1): 5–62. doi:10.22608/APO.2017436
21. Menke M.N., Framme C., Nelle M., et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3with plus disease. BMC Ophthalmol. 2015; 15: 20. doi:10.1186/s12886-015-0001-7
22. Alyamac S.E., Gomez A., Kocluk Y., et al. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. 2016; 236: 139–47. doi:10.1159/000449530
23. Neroev V.V., Katargina L.A. Active phase of retinopathy of prematurity. Klinicheskie recomendacii; 2017 (in Russian).
24. Beck K.D., Rahman E.Z., Ells A., et al. SAFER-ROP: Updated protocol for AntiVEGF injections for retinopathy of prematurity. Home ophthalmic surgery, lasers and imaging retina. 51 (7): 402–7. doi:10.3928/23258160-20200702-05
Review
For citations:
Lesovoy S.V., Boginskaya O.A. Applying Lucentis for the treatment of retinopathy of prematurity. Russian Ophthalmological Journal. 2022;15(4):45-48. (In Russ.) https://doi.org/10.21516/2072-0076-2022-15-4-45-48
Views:
1264
Email this article 